GLP-1-RA corrects mitochondrial labile iron accumulation and improves β-cell function in type 2 wolfram syndrome

Liron Danielpur, Yang Sung Sohn, Ola Karmi, Chen Fogel, Adar Zinger, Abdulsalam Abu-Libdeh, Tal Israeli, Yael Riahi, Orit Pappo, Ruth Birk, David H. Zangen, Ron Mittler, Zvi Ioav Cabantchik, Erol Cerasi, Rachel Nechushtai*, Gil Leibowitz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

39 Scopus citations

Abstract

Context: Type 2 Wolfram syndrome (T2-WFS) is a neuronal and β-cell degenerative disorder caused by mutations in the CISD2 gene. The mechanisms underlying β-cell dysfunction in T2-WFS are not known, and treatments that effectively improve diabetes in this context are lacking. Objective: Unraveling the mechanisms of β-cell dysfunction in T2-WFS and the effects of treatment with GLP-1 receptor agonist (GLP-1-RA). Design and Setting: A case report and in vitro mechanistic studies. Patient and Methods: We treated an insulin-dependent T2-WFS patient with the GLP-1-RA exenatide for 9 weeks. An iv glucose/glucagon/arginine stimulation test was performed off-drug before and after intervention. We generated a cellular model of T2-WFS by shRNA knockdown of CISD2 (nutrient-deprivation autophagy factor-1 [NAF-1]) in rat insulinoma cells and studied the mechanisms of β-cell dysfunction and the effects of GLP-1-RA. Results:Treatmentwithexenatideresultedina70%reductionindailyinsulindosewithimprovedglycemic control, as well as an off-drug 7-fold increase in maximal insulin secretion. NAF-1 repression in INS-1 cells decreased insulin content and glucose-stimulated insulin secretion, while maintaining the response to cAMP, and enhanced the accumulation of labile iron and reactive oxygen species in mitochondria. Remarkably, treatment with GLP-1-RA and/or the iron chelator deferiprone reversed these defects. Conclusion: NAF-1 deficiency leads to mitochondrial labile iron accumulation and oxidative stress, which may contribute to β-cell dysfunction in T2-WFS. Treatment with GLP-1-RA and/or iron chelation improves mitochondrial function and restores β-cell function. Treatment with GLP-1-RA, probably aided by iron chelation, should be considered in WFS and other forms of diabetes associated with iron dysregulation.

Original languageAmerican English
Pages (from-to)3592-3599
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume101
Issue number10
DOIs
StatePublished - Oct 2016

Bibliographical note

Publisher Copyright:
© 2016 by the Endocrine Society.

Fingerprint

Dive into the research topics of 'GLP-1-RA corrects mitochondrial labile iron accumulation and improves β-cell function in type 2 wolfram syndrome'. Together they form a unique fingerprint.

Cite this